Journalartikel

Jahr der Veröffentlichung: 2017

Seiten: V49-V52

Zeitschrift: Rheumatology

Bandnummer: 56

ISSN: 1462-0324

eISSN: 1462-0332

Open Access Status: Green

DOI Link: https://doi.org/10.1093/rheumatology/kex201

Verlag: Oxford University Press

Abstract: 
This article discusses points to consider when undertaking a clinical trial to test therapy for renal involvement in SSc, not including scleroderma renal crisis. Double-blind, randomized controlled trials vs placebo or standard background therapy should be strongly considered. Inclusion criteria should consider a pre-specified range of renal functions or stratification of renal function. Gender and age limitations are probably not necessary. Concomitant medications including vasodilators, immunosuppressants and endothelin receptor antagonists and confounding illnesses such as diabetes, kidney stones, hypertension and heart failure need to be considered. A measure of renal function should be strongly considered, while time to dialysis, mortality, prevention of scleroderma renal crisis and progression of renal disease can also be considered, although they remain to be validated. Detailed, pre-planned analysis should be strongly considered and should include accounting for missing data.

Harvard-Zitierstil: Galluccio, F., Mueller-Ladner, U., Furst, D., Khanna, D. and Matucci-Cerinic, M. (2017) Points to consider in renal involvement in systemic sclerosis, Rheumatology, 56, pp. V49-V52. https://doi.org/10.1093/rheumatology/kex201

APA-Zitierstil: Galluccio, F., Mueller-Ladner, U., Furst, D., Khanna, D., & Matucci-Cerinic, M. (2017). Points to consider in renal involvement in systemic sclerosis. Rheumatology. 56, V49-V52. https://doi.org/10.1093/rheumatology/kex201